Masimo Honors Birthday of Mahatma Gandhi With Global Holiday

IRVINE, Calif.–(BUSINESS WIRE)–Masimo (NASDAQ:
MASI) announced today that in honor of the birthday of Mahatma Gandhi
(October 2, 1869), the company will close worldwide and offer an
additional paid holiday to employees on Monday, October 3rd.

Mahatma Gandhi, born Mohandas Karamchand Gandhi, is considered the
preeminent leader of the Indian independence movement, famous for
seeking change, conflict resolution, and agreement through nonviolent
protest, often through public fasting. He is still honored today as a
global symbol of peace, with his birthday a national holiday in India
and celebrated worldwide as the International Day of Nonviolence.

“Masimo has chosen to honor Gandhi’s birthday to remind its employees
and partners worldwide of the enduring importance of those role models
who have helped shape our world for the better. At Masimo, we strive
each day to remain true to our promises and responsibilities,” said Joe
Kiani, Founder and CEO of Masimo. “For us, that includes being
thoughtful citizens of the world, striving to improve patient care
through our innovative products and technologies. In these difficult
times, when injustice, violence, and hatred are never far from the
headlines, it’s especially important to remember and admire the life of
one who so consistently embodied peace, forgiveness, and understanding.
Gandhi got what his people wanted and gained his country’s independence
from British rule through peaceful civil disobedience. I hope all Masimo
employees worldwide will use this extra day to take stock of their
lives, their goals, and their responsibilities, and to take steps to
create a more just and peaceful world.”

@MasimoInnovates |
#Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive
and continuous monitoring of blood constituents that previously could
only be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability
Index (PVI®) and Oxygen Reserve Index (ORi™), in addition to
SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect™ (MOC-9™) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo’s unique noninvasive measurement
technologies contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique advantages; as
well as other factors discussed in the “Risk Factors” section of our
most recent reports filed with the Securities and Exchange Commission
(“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today’s date. We do not undertake any obligation to update, amend or
clarify these statements or the “Risk Factors” contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.

Contacts

Media Contact:
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com

?>